Atibuclimab is a chimeric monoclonal antibody targeting CD14, comprised of murine variable regions and human IgG4 Fc regions. This antibody is specifically designed for research purposes in amyotrophic lateral sclerosis (ALS). Atibuclimab effectively moderates lipopolysaccharide (LPS)-induced symptoms and robustly suppresses the release of proinflammatory cytokines induced by LPS. Concurrently, it moderately delays the secretion of anti-inflammatory cytokines, including soluble TNF receptor type I and IL-1 receptor antagonist, providing a distinct profile of cytokine regulation. This dual action makes Atibuclimab a valuable tool for investigating inflammatory pathways and their modulation in ALS research.
Atibuclimab is a chimeric monoclonal antibody targeting CD14, comprised of murine variable regions and human IgG4 Fc regions. This antibody is specifically designed for research purposes in amyotrophic lateral sclerosis (ALS). Atibuclimab effectively moderates lipopolysaccharide (LPS)-induced symptoms and robustly suppresses the release of proinflammatory cytokines induced by LPS. Concurrently, it moderately delays the secretion of anti-inflammatory cytokines, including soluble TNF receptor type I and IL-1 receptor antagonist, providing a distinct profile of cytokine regulation. This dual action makes Atibuclimab a valuable tool for investigating inflammatory pathways and their modulation in ALS research.
This calculator helps you calculate mass of compound based on solution concentration, volume and molecular weight in a specific solution using the formula:
